Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of biopharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group has two GMP manufacturing bases in Beijing and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine as diabetes and osteoporosis, ophthalmology and dermatology. Please visit the official website of Uni-Bio Science Group for more information: www.uni-bioscience.com/
About Chengdu Medlinker Technology Company Limited (Medlink)
Medlink is one of first online healthcare platforms acquiring license of online hospital. As to May 2019, 3.5 million of online prescription had been made. From 2018, Medlink leverages technology advantages of internet combining AI and healthcare big data, and focuses on chronic disease management, to provide long-term regulated chronic disease management service for massive patients. The platform now gathers more than 800,000 real-name registered doctor and 48,000 contract doctor, covering twelve chronic disease areas including herpetological disease, diabetes, HIV, cancer, nephropathic disease and cardiovascular disease, and provides integrated online healthcare service and drug delivery service, allowing patients to have high-quality healthcare service without stepping out their home. Please visit the official website of Medlink for more information: https://www.medlinker.com/
About GeneTime®（Recombinant human epidermal growth factor topical solution (I) ）
Uni-Bio Science Group's proprietary product Genetime® is a patented spray formulation of Recombinant Human Growth Factor (rhEGF), which is safe and convenient for administration. GeneTime® speeds up wound healing and reduces scar formation, and can be used in a wide range of hospital departments, including burns, dermatology, obstetrics and aesthetic departments. The prescription biological drug is manufactured via high-tech gene engineering and microbial fermentation techniques. GeneTime® comes in two specifications: 15ml and 5ml (2000IU/ml). GeneTime® belongs to a national class one new drug and national reimbursement list B drug. It has clear clinical value and is recommended by authoritative medical guidelines, including China National Health Department's textbook: "Oral mucosal diseases"4th edition, "China wound therapy guide 2015", "China diabetic foot therapy guide 2017". According to research by Guangzhou Biaodian Medical Information, each year PRC has over 5-10 million burns patients, 5.5 million patients with diabetic foot ulcers, and over 7.33 million patients with skin bedsores. The patient amount of aesthetic medicine, including laser and photon freckle removal, has also been increasing significantly year by year. Hence, the Chinese market for rhEGF was 702 million RMB in 2019, and is expected to be over 1.42 billion RMB in 2024, a 5-year CAGR of 15.08%.